Shirley Ann Jackson, Ph.D. Elected to Albany Molecular Research, Inc. Board of Directors.

Business Editors

ALBANY, N.Y.--(BUSINESS WIRE)--July 27, 2001

Albany Molecular Research, Inc. (Nasdaq: AMRI) today announced the election of Shirley Ann Jackson, Ph.D. to its Board of Directors. This election fills a newly created position.

A prominent physicist and

university president, Dr. Jackson has served since 1999 as president of Rensselaer Polytechnic Institute, one of the nation's leading technological and research universities, located in Troy, New York. Before assuming the presidency at Rensselaer, she was chairman of the U.S. Nuclear Regulatory Commission (NRC) from 1995-1999 under former President Clinton, and a professor of physics at Rutgers University from 1991 to 1995. Dr. Jackson worked as a theoretical physicist at the former AT&T Bell Laboratories during the period 1976 to 1991.

"We are delighted to have Dr. Jackson on our Board," said Albany Molecular Research, Inc. Chairman and Chief Executive Officer Thomas E. D'Ambra, Ph.D. "Dr. Jackson brings a strong scientific background as a physicist and university administrator, along with extensive experience in industry, academia and government. She is a visionary leader and driven individual who has instituted significant change and improvement at Rensselaer. Her wisdom and experience will be valuable to AMRI."

Soon after assuming leadership at Rensselaer, Dr. Jackson launched a comprehensive and ambitious strategic plan to enhance research and upgrade Rensselaer's status as a leading university, particularly in the areas of biotechnology and information technology. D'Ambra continued, "We think that Rensselaer's strategic focus in biotechnology research, along with related biotechnology research collaborations between Rensselaer and other university and government organizations in the Albany area, will provide excellent vehicles to strengthen academic and industrial ties locally."

Dr. Jackson becomes the seventh member of the AMRI Board of Directors. She received her undergraduate degree from MIT in physics and a doctorate in theoretical physics from MIT in 1973. For 15 years, Dr. Jackson conducted research in theoretical physics, solid state and quantum physics, and optical physics at AT&T Bell Laboratories. While Dr. Jackson was a professor of physics at Rutgers from 1991 to 1995, she also served as a consultant to Bell Labs. In 1995, Dr. Jackson was appointed by former President Clinton as chairman of the US Nuclear Regulatory Commission, where she served until her appointment at Rensselaer. While at the NRC, Dr. Jackson was elected chair of the International Nuclear Regulators Association, which is composed of senior nuclear regulatory officials from Canada, France, Germany, Japan, Spain, Sweden, the United Kingdom and the United States. For four years, she represented the U.S. at the General Conference of the International Atomic Energy Agency in Vienna, Austria.

Dr. Jackson is a member of the National Academy of Engineering and the American Academy of Arts and Sciences. She is a Life Member of the MIT Corporation (MIT's Board of Trustees). In addition to her position at AMRI, Dr. Jackson also serves as a director of FedEx Corporation, AT&T, Public Service Enterprise Group, Sealed Air Corporation, Newport News Shipbuilding, USX Corporation, and SCI Systems Inc.

Albany Molecular Research, Inc. is a chemistry based drug discovery and development company, focusing on applications for new small molecule prescription drugs. The company conducts R&D projects and collaborates with many leading pharmaceutical, biotechnology and genomics companies, and is developing new chemistry technology for potential prescription drug applications.

Statements in this press release that are not historical facts are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that involve risks and uncertainties. The company's actual results may differ materially from such forward-looking statements. Factors that could cause such differences include, but are not limited to, the company's ability to attract and retain experienced scientists, trends in pharmaceutical and biotechnology companies outsourcing chemical research and development, sales of Allegra(R) and the company's receipt of royalties from the Allegra license agreement, the possibility that Allegra will be approved by the FDA for over-the-counter sales and the potential adverse effects to the company's licensing revenues as a result of such determination, the company's ability to enforce its intellectual property and technology, the company's ability to take advantage of proprietary technology and expand the scientific tools available to it, the ability of the company's strategic investments and acquisitions to perform as expected, the company's ability to successfully complete its ongoing expansion projects on schedule and integrate acquired companies, and the company's ability to effectively manage its growth, as well as those discussed in the company's Annual Report on Form 10-K for the year ended December 31, 2000 as filed with the Securities and Exchange Commission on April 2, 2001 and the company's other SEC filings.